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Summary Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal
breast cancer patients. Age, oestrogen (ER) and progesterone (PR) receptor status are accurately considered to
select patients for hormonal treatment. However, additional markers are needed. By immunohistochemistry
(IHC), we studied tumour expression of ER, PR, pS2, c-erbB-2 and glutathione S-transferase 7r (GSTh) on
initial core biopsies of 208 post-menopausal patients with a non-metastatic invasive ductal carcinoma, treated
by neoadjuvant tamoxifen therapy. A good response to tamoxifen was defined as tumoral regression >50%
(110 patients). Relationship between response and age, tumour size, T, N, histological grade, ER and PR
contents evaluated by radioimmunoassay, ER, PR, pS2, c-erbB-2 and GSTx expression evaluated by IHC were
studied. Univariate and multivariate analysis showed that tumoral regression was linked only to pS2 (P=0.004)
and ER (P=0.018) IHC expression. According to the immunohistochemical profile, three groups could be
defined: pS2- and ER-positive tumours, pS2- or ER-positive tumours and pS2- and ER-negative tumours with
response rates of 60%, 45% and 8% respectively. Although prospective studies are needed to confirm these
results, we conclude that pS2 and ER immunohistochemical status are useful tools for predicting tumour
regression with neoadjuvant tamoxifen in post-menopausal breast carcinoma patients.
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The incidence of breast neoplasm increases with age. One-
third of cases affect women older than 65 years. However,
management of breast carcinomas in the elderly remains
controversial. While some authors defend surgical treatment
(Robertson et al., 1992a), others have demonstrated the
advantage of tamoxifen as sole initial therapy (Gazet et al.,
1988; Akhtar et al., 1991; Horobin et al., 1991; Foudraine et
al., 1992; Bergman et al., 1995). In two randomised studies
(Gazet et al., 1988; Robertson et al., 1992a), no difference in
survival was found between the surgical and tamoxifen
groups. Robertson et al observed only a better locoregional
control in the mastectomy group, although not statistically
significant. In fact, in elderly and frail patients, shorter life
expectancy, concomitant diseases and increased surgery risk
are prominent factors determining treatment choice. How-
ever, there is no precise way of knowing which patients can
be treated with tamoxifen only as primary treatment. Until
now, age and hormonal receptor status have been the main
factors for identifying patients with hormone-sensitive
tumours. Yet, in post-menopausal cohorts of breast cancer
patients, in spite of a high proportion of ER-positive
tumours, 30% to 60% of patients fail to respond to primary
tamoxifen therapy (Gaskell et al., 1989; Akhtar et al., 1991;
Horobin et al., 1991; Robertson et al., 1992a; Foudraine et
al., 1992; Bergman et al., 1995). So it seems essential to look
for additional markers of hormone responsiveness.
New insights into immunohistochemical techniques and
new antibodies available make retrospective studies possible.
In addition to ER and PR, new proteins more or less linked
to hormonal receptors (HRs) have recently been isolated.
Their role as prognostic factors and hormone-responsiveness
markers has been suggested. Among them, we decided to
examine pS2 protein, glutathione S-transferase ir (GSTx) and
c-erbB-2 oncogene. pS2 protein was first identified in the
human breast cancer cell line MCF-7 in response to
oestrogen stimulation (Masiakowski et al., 1982). Recently,
it has been proposed as a candidate for prediction of
hormone-related tumour regression (Henry et al., 1989;
1991; Schwartz et al., 1991; Hurlimann et al., 1993; Wilson
et al., 1994). Similarly, c-erbB-2 proto-oncogene, whose
prognostic value in breast carcinomas is still controversial,
has recently been implicated in predicting hormone-related
tumour regression (Wright et al., 1992; Nicholson et al.,
1993). GSTm enzyme is thought to play a role in the
intracellular detoxification of a wide range of xenobiotics and
anti-neoplastic drugs. In a preliminary study using dot-blot
mRNA hybridisation, we found a link between response to
tamoxifen therapy and low levels of GSTir mRNA (Dorion-
Bonnet et al., 1993).
For these reasons, we have studied immunohistochemical
expression of ER, PR, pS2, GSTi and c-erbB-2 in a series of
208 non-metastatic post-menopausal patients with primary
invasive breast carcinomas first treated in our centre by




From 1984 to 1990, 2835 new patients with primary non-
metastatic invasive ductal breast carcinomas were treated in
our Comprehensive Cancer Center. Among them, 251 post-
menopausal patients were first treated by neoadjuvant
hormonal therapy (tamoxifen) for 5 months, for locally
advanced HR-positive tumours. Of these 251 women, 43 were
excluded: 26 because of insufficient histological material for
IHC assays, two because of a bilateral tumour, one for
concomitant chemotherapy and four owing to the patient's
refusal to pursue hormonal therapy. Additionally, six patients
were lost to follow-up and four died of intercurrent disease
within the first 2 months. Patients who died from cancer or
had a secondary treatment for progressive disease during this
period were considered in progression and retained for the
study.
All the 208 remaining patients underwent a core biopsy
before treatment. At the time of diagnosis, patients were
staged according to the UICC TNM classification. The two
largest tumour diameters were clinically measured. Oestrogen
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April 1996and progesterone receptor status was determined by the
dextran-coated charcoal method (DCC) with a cut-off level
for hormone dependency of 10 and 15 fmol mg-' of protein
respectively. Patients received orally 30 mg tamoxifen daily
for 5 months. Tumour response was evaluated at this time by
clinical examination. Good response (group A) was defined
as either complete or partial response >50%, whereas
decrease in size <50% static disease and progression were
regarded as no or insufficient response (group B). A total of
110 patients entered group A (22 with complete remission
and 88 with partial remission >50%) and the remaining 98
patients entered group B (50 with partial remission <50%,
33 with stable disease and 15 with progressive disease).
At that time, secondary treatment was decided upon by a
multidisciplinary team according to clinical response,
possibility of surgery, patient's age, tamoxifen tolerance or
the patient's wishes. Of the 208 patients, 57 pursued
hormonal therapy (tamoxifen or second-line therapy), 67
were irradiated, 10 received chemotherapy and 74 were
operated on [either Patey surgery (n= 37) or wide local
tumour excision (n = 37) with axillary clearance].
Characteristics of patients were as follows: mean age, 72
years (range, 48-89 years); nodal status, <N1B = 121 (58%),
N1B= 87 (42%); median tumoral diameter, 43 mm (range,
15-160 mm); ER (DCC) status, ER-negative= 28 (13.5%),
ER-positive = 176 (84.5%), unknown=4 (2%); PR (DCC)
status, PR-negative= 81 (39%), PR-positive= 116 (56%),
unknown= 1I (5%); both HR-positive = 106 (51%). For the
whole group, the median follow-up was 44 months (range,
9-116 months) with none lost to follow-up. Five year overall
survival and time to progression were 56.7% and 62.8%
respectively (Figure 1). Core biopsies were reviewed at the
time of the study for selection of blocks with sufficient
infiltrating tumour cells, and for grading using the Scarff,
Bloom and Richardson (SBR) method. We found 40 tumours
of grade 1 (19%), 117 grade 11(56%) and 51 grade III (25%).
Immunohistochemistry
Assay procedures Immunohistochemical studies for ER, PR,
pS2, GSTx and c-erbB-2 were carried out on pretreatment core
biopsies. ER assay was done with a mouse monoclonal
antibody clone iD5 (Dako), diluted 1:25 and applied for
45 min at room temperature. PR rat monoclonal antibody
(Abbott) was diluted 1:10 and applied overnight at room
temperature. The monoclonal antibody Histocis pS2` (Cis
Bioindustries, France) was diluted 1:10 and applied overnight
at 4°C. For c-erbB-2 determination we used a rabbit polyclonal
antibody (Dako) diluted 1:600 and applied for 10 min at room
temperature. Dr K Cowan very kindly provided us with a
rabbit polyclonal antibody anti-GSTi which was diluted
1:3000 and applied for 2 h at room temperature.
Bouin -Holland-fixed paraffin-embedded sections were cut
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Figure 1 Overall survival (-) and time to progression (-)
curves of the whole group (208 patients).
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For hormonal receptor assays, sections were pretreated by
immersing in citrate buffer (0.01 M, pH 6) and heating at
high power in a microwave for two periods of 5 min. The
streptavidin-biotin-peroxidase method was performed as
previously described (Soubeyran et al., 1995) according to
manufacturer's instructions with the Strept ABComplex/
HRP Duet Kit (Dako) for hormonal receptor assays, and
with the LSAB Kit (Dako) for pS2, c-erbB-2 and GSTir
assays. Finally, sections were reacted with DAB [substrate
solution, 0.09% hydrogen peroxide in phosphate-buffered
saline (PBS)] for 5 min, rinsed and counterstained with fast
green for hormonal receptors and with hematein for other
antibodies. Nuclear staining was expected for ER and PR,
cytoplasmic immunoreactivity for pS2 and GSTx and
membrane labelling for c-erbB-2. Appropriate control
slides, positive and negative cases, were included in each
series.
Validity of assays To assess the validity of immunohisto-
chemistry (IHC), each of the five assays was prospectively
compared in series of recent infiltrating breast carcinoma
cases to one or more standard techniques. For pS2, c-erbB-2
and hormonal receptors, these results have been reported
previously (Soubeyran et al., 1995; Quenel et al., 1995; de
Mascarel et al., 1995). For GSTT, a comparison was made in
73 cases between IHC assay and dot-blot mRNA analysis.
For dot-blot analysis, positivity was defined relative to a
control cell line (Dorion-Bonnet et al., 1993). The agreement
between IHC assay and dot-blot mRNA analysis was of
78%, sensitivity 100% and specificity 71%.
Evaluation of the series The pretreatment core biopsies were
then tested by IHC. For each antibody, all the slides were
read by the same person (JMC or IS) and borderline cases
were reviewed together. IHC analysis was performed without
knowledge of clinical data or outcome. An evaluation of
semi-quantitative staining features was made, by noting the
percentage of positive infiltrating tumour cells and the
staining intensity. The percentage of these cells was
estimated from the whole section and ranged from 0% to
100%. Staining intensity was subjectively scored on a 0-3+
scale, with 1 representing faint but distinct staining, 3 intense
staining and 2 an intermediate level. For each case, a score
was obtained by multiplying the percentage of positive cells
by the intensity (range, 0 to 300). With statistical analysis, it
appeared that results were similar using either percentages or
scores. Therefore for simplicity, only percentage results are
shown for all five markers.
According to Simon et al. (1994) and Hill (1993), cut-off
points were predefined in agreement with previous reports.
For ER and PR, a cut-off level of 10% positivity was
retained (Pertschuck et al., 1990; Gilbert et al., 1993; de
Mascarel et al., 1995). For pS2, the threshold chosen was 3%
according to previous results (Soubeyran et al., 1995). For
GSTir and c-erbB-2, tumours were considered as positive as
soon as there were stained infiltrating tumour cells, either
cytoplasmic (GSTi) or membrane labelling (c-erbB-2)
whatever the intensity (Gilbert et al., 1993; Rilke et al., 1991).
Statistical analysis
The chi-square test was used to test the relationship between
immunohistochemical parameters, clinical factors and clinical
response to hormonal therapy. Survival curves were
established by the Kaplan-Meier method. All patients were
followed up every 3 months until death. For overall survival
(OS), survival duration was calculated from the date of core
biopsy to death or the date they were last known alive. All
causes of death were considered as events. Time to
progression was computed from the date of biopsy until
metastasis, relapse or progression. Patients who died from
unrelated causes were considered as censored by the time of
their death. The cut-off date for the current analysis was 1
September 1993. Multivariate analyses were performed
..IPrediction of tamoxifen response
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stepwise with the Cox regression model using BMDP
software, Program LR. The variable tested was the
attainment of a good response.
Results
Immunohistochemical assays
ER positivity () 10%) was noted in 172 core biopsies
(82.5%) while four cases (2%) had less than 10% of stained
infiltrating tumour cells and 32 (15.5%) were completely
negative. Intensity was most often faint: 44% of intensity 1,
32% of intensity 2 and 24% of intensity 3.
PR nuclear staining was observed in 131 cases (63%) with
more than 10% of stained infiltrating tumour cells, and with
less than 10% of stained tumour cells in 18 cases (9%). Fifty-
nine core biopsies (28%) were negative. Staining intensity was
level 1 in 31.5% of cases, level 2 in 51.5% and 3 in 17%.
Cytoplasmic pS2 staining was noted in 183 cases with 153
core biopsies (73.5%) showing more than 3% of stained cells
and 30 (14.5%) less than 3%. Twenty-five tumours (12%)
were negative. Intensity was distributed as follows: 29% level
1, 41% level 2, 30% level 3.
For GSTx, a cytoplasmic staining was noted in 95 core
biopsies (46%) while more than a half (113 cases,=54%)
were negative. Intensity was most often level 2 (49.5%), was 1
in 21% and 3 in 29.5% cases. C-erbB-2 membrane labelling
was observed in 66 tumours (32%) with 48.5% of level 1,
41% of level 2 and 10.5% of level 3. No staining was noted
in 142 tumours (68%).
Relationship between IHC parameters and clinical factors
For each of the five IHC parameters, relationship with age,
clinical diameter, T and N of the TNM staging were tested.
In this series of post-menopausal patients, a significant
relationship was found between ER positivity and age <70
years (P=0.02). ER was linked neither to diameter nor to T
or N status. Another relationship was observed between
GSTi negativity and age <70 years (P=0.04) on the one
hand, and clinical diameter>35 mm (P=0.01) on the other.
No other significant correlation was observed between other
markers and clinical parameters.
Inter-relationship between IHC parameters
Similar results were observed when the various IHC
markers were crossed one to one. Only c-erbB-2 and
PR IHC were inversely correlated (P =0.03). No link was
found between ER IHC and PR IHC, ER IHC and pS2,
ER IHC and GSTi, ER IHC and c-erbB-2. Moreover, no
correlation was observed between PR IHC and pS2,
PR IHC and GSTr, pS2 and GSTr, pS2 and c-erbB-2,
GSTir and c-erbB-2.
Relationship between IHC parameters and histological SBR
grade
SBR grade and its three parameters (i.e. tubular formation,
mitotic rate and nuclear polymorphism) were crossed with
IHC markers. No relationship was found between grade and
ER IHC, PR IHC and pS2. GSTx negativity was linked to
grade III (P=0.003) and to less differentiated tumours
(P=0.0035). A weak link was observed between c-erbB-2
negativity and grade I vs grade II/III (P=0.05).
Relationship between clinical response and classicalfactors
Age <70 years, clinical diameter >35 mm, T <T4, N<N1B,
ER (DCC)<10 fmol mg-', PR (DCC)<15 fmol mg- and
SBR grade were tested for prediction of tumour reduction
(Table I). A single relationship was found between good
response and ER (DCC) positivity with a P-value close to
significance (P =0.06).
Relationship between clinical response and IHC parameters
ER IHC>10%, PR IHC>10%, pS2>3%, GSTr>0 and c-
erbB-2>0 were crossed with group A (responders) and group
B (non-responders). Results are shown in Table II. A
significant relationship was found between ER IHC positiv-
ity and a good response (P= 0.016). Additionally, we
observed a strong relationship between pS2 positivity and a
good response with a P-value=0.006. Response to hormonal
therapy was correlated neither with PR IHC nor with GSTx
or c-erbB-2.
Analysis of discrepancies between ER (DCC) and ER IHC
results
Analysis of discrepancies revealed ten cases in the ER IHC-
positive/ER (DCC)-negative group. Six (60%) responded to
tamoxifen, three (30%) showed partial regression and one
Table I Relationship between clinical response and classical
predictive factors
Number of Responders Non-responders
patients No. (%) nb (%) P-value
Age (years)
<70 78 39 (50) 39 (50) NS (0.55)
>70 130 71 (55) 59 (45)
Diametera
>35 61 32 (52) 29 (48) NS (0.94) >35 145 77 (53) 68 (47) NS(.4
Ta
<T4 108 53 (49) 55 (51) NS (0.3)
=T4 99 56 (57) 43 (43)
N
<NIB 121 66 (55) 55 (45) NS (0.7)
,>NIB 887 44 (51) 43 (49)
Grade
I 40 22 (55) 18 (45)
II NS (0.9)
III 117 62 (53) 55 (47)
ER (DCC)a
<10 fmol 28 10 (36) 18 (64)
>10 fmol 176 99 (56) 77 (44)
PR (DCC)a
<15 fmol 81 48 (59) 33 (41) NS (0.2)
kl5 fmol 116 57 (49) 59 (51)
aNumber of cases does not always tally because some data are
missing
Table II Relationship between clinical response and IHC para-
meters
Number of Responders Non-responders
patients No. (%) nb (%) P-value
pS2
<3% 55 20 (36) 35 (64) 0006
,>3% 153 90 (59) 63 (41)
ER
< 10% 36 12 (33) 24 (67) 0.016
>10% 172 98 (57) 74 (43)
GSTx
=0% 113 64 (57) 49 (43) NS (0.3) .1% 95 46 (48) 49 (52)
PR
<10% 77 42 (55) 35 (45) NS (0.8)
>,10% 131 68 (52) 63 (48)
c-erbB 2
=0% 142 74 (52) 68 (48) NS (0.8)
,- 1% 66 36 (55) 30 (45)Prediction of tamoxifen response
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(10%) showed progression. On the other hand, there were 15
cases in the ER IHC-negative/ER (DCC)-positive group of
whom eight (53.3%) were good responders, five (33.3%)
showed partial response, one (6.7%) remained stable and one
(6.7%) progressed. Regarding tamoxifen response there was
no statistical difference between the two groups (Fisher test,
P=0.53). Combining the two methods, the analysis showed
81% (17/21) of non-responders in the ER IHC/ER (DCC)-
negative group whereas 56.7% (106/187) of responders
against 43.3% (81/187) of non-responders in the ER IHC
and/or ER (DCC)-positive group.
Multivariate analysis
Eleven factors were included in the Cox regression model:
ERIHC<10%, PRIHC<10%, pS2<3%, GSTr=0, c-
erbB-2 = 0, grade III, less differentiated tumours, age>70
years, N>N1 T=T4, clinical diameter>35 mm. Three
patients had factors missing and were not included. Two
factors were significant for predicting hormonal tumour
response: pS2>3% (P=0.004) and ER IHC, 10%
(P=0.018). According to immunohistochemical profile, four
groups of patients were defined. In Table III, the rate of
objective response is shown in each group as well as the
predictive value of the model (i.e. response rate expected for a
new patient).
From a practical point of view, three groups of patients
can be defined:
Group 1 (pS2-positive/ER-positive) 62% of expected response
Group 2 (pS2-positive or ER-positive) 40% of expected response
Group 3 (pS2-negative/ER-negative) 22% of expected response
Discussion
Tamoxifen has been advocated as first-line therapy in post-
menopausal patients with locoregional disease for several
reasons. It has a low toxicity with few side-effects. It can offer
tumour regression before surgery and may represent an
alternative to surgery or radiotherapy in frail patients, thus
allowing good initial remission rates (Akhtar et al., 1991;
Foudraine et al., 1992). Unlike Bergman et al. (1995), who
showed a low response rate of 37.6%, we observed a good
5 month remission rate of 53% (with the same regression rate
of at least 50%). This rate rose to 77% with inclusion of
minor responses (25-50%). This should certainly be
attributed to the high percentage of ER-positive tumours in
our series (84.6% by DCC and 82.5% by IHC). In fact, this
is higher than expected in a group of post-menopausal
women. Most of the patients who entered neoadjuvant
tamoxifen therapy had an HR-positive tumour, either both
ER and PR or one of those. Only 18 tumours (9%) by DCC
and 15 tumours (7%) by IHC were both ER and PR
negative.
Although delayed response can be obtained with
tamoxifen therapy (Bergman et al., 1995), we chose to
evaluate tumour response after 5 months of treatment for
several reasons. First of all, most responses appear to occur
Table Ill Multivariate analysis: predictive value of immunohisto-
chemical profile
Number of Number ofgood Predictive value
pS2 ER patients responders % ofmodel %
- - 13 1 (8) 22
- + 42 19 (45) 41
+ 23 11 (48) 40
+ + 127 77 (60) 62
during the first 5 months (Gaskell et al., 1989; Akhtar et al.,
1991; Robertson et al., 1992a; Bergman et al., 1995).
Moreover, some patients could benefit from a secondary
treatment that we did not wish to delay. This latter point
remains controversial (Bradbeer et al., 1983; Gazet et al.,
1988; Akhtar et al., 1991; Robertson et al., 1992a; Bergman
et al., 1995) and the present study cannot elucidate this point
since most of our patients had a secondary treatment and
only 57 patients pursued hormonal treatment (tamoxifen or
second-line hormonal therapy). Evaluation at 5 months was
done by a multidisciplinary team to reduce subjectivity. It
was more clinical than on a mammogram, because
radiological changes are often delayed with regard to clinical
response. It seemed to us reasonable to define good response
as tumour regression , 50% because we proposed a
neoadjuvant therapy for locally advanced but non-metastatic
tumours. Therefore, it was important in such conditions to
obtain a real benefit for patients.
Hormonal receptor status was initially determined by the
DCC method routinely used in our institution for the last
15 years. It was done on pretreatment core biopsies and
cellularity of samples was controlled by cytological touch-
prep of the biopsy. Despite the well-known tumour
heterogeneity for HR expression, HR status determined on
core biopsies or fine-needle aspirates is reliable. In fact,
good agreement is found with HR status determined on
surgical specimens (Mauriac et al., 1981; Katz et al., 1990;
Frigo et al., 1995). Furthermore, HR status determined
either on core biopsies or on fine-needle aspirates maintains
its predictive value on prognosis and on tumour respon-
siveness to hormonal treatment (Coombes et al., 1987;
Mauriac et al., 1989; Gaskell et al., 1989, 1992; Davies et
al., 1991). Immunohistochemistry has both several advan-
tages and limitations with regards to the DCC method, a
theme widely discussed elsewhere (Pertschuk et al., 1985;
McClelland et al., 1986; Hurlimann et al., 1993; de
Mascarel et al., 1995). As previously reported by some
authors (McCarty et al., 1985; Pertschuk et al., 1985, 1990;
McClelland et al., 1986; Robertson et al., 1992b; Hurlimann
et al., 1993), both methods show a link between ER
positivity and tumour regression, yet in all these series, the
immunohistochemical technique appeared to be a better
predictor of response to hormone therapy with better
specificity. Moreover, IHC appears to us to offer the
advantage of being done on the specimen used for
histological examination allowing control of the positive
cells (i.e. infiltrating tumour cells vs intraductal component
or normal mammary tissue), thereby avoiding multiple
biopsies.
By analysing correlations between immunohistochemical
factors and clinical parameters, we found an inverse
correlation between age and ER. This unexpected finding
could be explained by a selection bias of the series. As a
matter of fact, only 7 of 78 patients (9%) under 70 years had
ER-negative tumours because these patients were preferably
treated by first-line surgery, radiotherapy or chemotherapy.
On the contrary, in women aged 70 or over, it is justifiable to
propose first-line hormonal treatment especially in frail
patients and even for ER-negative tumours (Williams et al.,
1988; Horobin et al., 1991; Akhtar et al., 1991). In our series,
29/130 patients (22%) were 70 or over and had ER-negative
tumours. Some expected correlations such as grade and HR
status, on the one hand, and ER status and pS2, GSTir, c-
erbB-2 on the other, were not observed in this series. It may
be that this is an artefact due to our high content of ER-
positive tumours.
Regarding the prediction of clinical response to tamoxifen
at 5 months, it is worthy of note that only two factors are
predictive: ER and the newly described pS2 protein. As
already found by other authors (Henry et al., 1989, 1991;
Schwartz et al., 1991; Hurlimann et al., 1993; Wilson et al.,
1994) except one (Luqmani et al., 1993), we confirm in our
series the relevance of pS2 to predict tamoxifen-related
tumour regression, especially when combined with ER
r12Prediction of tamoxifen response
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status. We also note that pS2 alone was as predictive as ER
alone and that pS2 expression was not linked to ER status.
This strengthened its value in the logistic regression analysis.
Only one of 13 patients with both pS2- and ER-negative
status responded to tamoxifen while 60% (77/127) with both
positive markers did, as well as 45-48% of those with either
one. These results may appear lower than expected, but it has
to be stressed that we chose to consider only responses
superior to 50% of tumour regression. In this series,
consideration of both markers improved predicition of
tamoxifen-related tumour regression
We did not find any link between c-erbB-2 expression and
response to primary tamoxifen therapy. The two previous
studies (Wright et al., 1992; Nicholson et al., 1993) were done
in series different from ours, concerning either recurrences or
an admixture of locally advanced primary tumours and
relapses. Both studies showed a significant but weak
relationship between c-erbB-2 positivity and reduced re-
sponse rate. It is difficult to know whether these divergent
results are related to the differences between our series and
the others, or if c-erbB-2 is definitely not a powerful
candidate for predicting hormone responsiveness.
PR status is classically supposed to reflect the functionality
of the oestrogen receptor. Combined with the latter, it is
considered to improve prediction of response to endocrine
therapy (Ravdin et al., 1992; Klijn et al., 1993). Surprisingly,
In this series, it did not help to identify hormone-responsive
tumours. This unexpected finding was previously reported by
other authors (Schwartz et al., 1991; Hurlimann et al., 1993).
In cases of adjuvant or palliative therapy, a discordance in
steroid receptor content between primary and metastatic
lesions could certainly be ascribed since progressive disease is
thought to correlate with tumour dedifferentiation or
development of poorly differentiated clones. However, this
does not concern our series since steroid receptor assessment
and tamoxifen-related tumour regression were done on
primary tumours. So although tamoxifen is thought to act
mainly through oestrogen receptors, mechanisms of tumour
responsiveness or resistance seem to be much more complex.
To investigate tamoxifen's molecular effects, we studied
immunohistochemical changes of ER, PR, pS2, GST7r and
c-erbB-2 under tamoxifen therapy in the group of 74 patients
operated on after 5 months of tamoxifen. These results are
reported in another paper (Soubeyran et al., 1996).
Finally, these promising results warrant further considera-
tion of pS2 as being an important candidate for predicting
tamoxifen-induced regression of breast carcinomas in both
post-menopausal patients and perhaps in younger patients.
Prospective studies are required to confirm these data and
improve them by testing new markers.
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